Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity | springermedicine.com

Springer Medicine

Top

Published in:

01-08-2010 | Article

Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity

Authors: D. Jacobs-Tulleneers-Thevissen, K. Bartholomeus, K. Suenens, I. Vermeulen, Z. Ling, K. H. Hellemans, P. In’t Veld, M. Pipeleers-Marichal, D. Pipeleers

Published in: Diabetologia | Issue 8/2010

Login to get access

Abstract

Aims/hypothesis

Intraportal human islet cell grafts do not consistently and sustainably induce insulin-independency in type 1 diabetic patients. The reasons for losses in donor cells are difficult to assess in patients. This study in streptozotocin-diabetic nude rats examines whether outcome is better in an extra-hepatic site such as omentum.

Methods

Intraportal and omental implants of human islet cell grafts with the same beta cell number were followed for function and cellular composition over 5 weeks. Their outcome was also compared with that of rat islet cell grafts with similar beta cell numbers but higher purity.

Results

While all intraportal recipients of rat islet cell grafts were normoglycaemic until post-transplant (PT) week 5, none was with human islet cell grafts; loss of human implants was associated with early infiltration of natural killer and CD45R-positive cells. Human islet cell implants in omentum achieved plasma human C-peptide positivity and normoglycaemia in, respectively, nine of 13 and five of 13 recipients until PT week 5; failures were not associated with inflammatory infiltrates but with lower beta cell numbers and purity of the grafts. Observations in human and rat islet cell implants in the omentum suggest that a delayed revascularisation can interfere with their metabolic outcome. Irrespective of normalisation, human omental implants presented beta cell aggregates adjacent to alpha cells and duct cells.

Conclusions/interpretation

In nude rats, human islet cell implants survive better in omentum than in liver, with positive influences of the number and purity of implanted beta cells. These observations can guide studies in patients.

Available only for authorised users

1.

Ryan EA, Paty BW, Senior PA et al (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069CrossRefPubMed

2.

Keymeulen B, Gillard P, Mathieu C et al (2006) Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A 103:17444–17449CrossRefPubMed

3.

Bennet W, Sundberg B, Groth CG et al (1999) Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48:1907–1914CrossRefPubMed

4.

Schuurman HJ, Hougen HP, Loveren HV (1992) The rnu (Rowett nude) and rnu ^N (nznu, New Zealand nude) rat: an update. ILAR Journal V34. Available from http://dels.nas.edu/ilar_n/ilarjournal/34_1_2/34_1_2rnuRat.shtml

5.

Lake SP, Chamberlain J, Bassett PD et al (1989) Successful reversal of diabetes in nude rats by transplantation of isolated adult human islets of Langerhans. Diabetes 38:244–248CrossRefPubMed

6.

Keymeulen B, Anselmo J, Pipeleers D (1997) Length of metabolic normalization after rat islet cell transplantation depends on endocrine cell composition of graft and on donor age. Diabetologia 40:1152–1158CrossRefPubMed

7.

Keymeulen B, Korbutt G, De Paepe M, Gorus F, Klöppel G, Pipeleers DG (1996) Long-term metabolic control by rat islet grafts depends on the composition of the implant. Diabetes 45:1814–1821CrossRefPubMed

8.

Pipeleers DG, Pipeleers-Marichal M, Vanbrabandt B, Duys S (1991) Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet beta-cells. Diabetes 40:920–930CrossRefPubMed

9.

Pipeleers D, Keymeulen B, Chatenoud L et al (2002) A view on beta cell transplantation in diabetes. Ann N Y Acad Sci 958:69–76PubMedCrossRef

10.

Keymeulen B, Ling Z, Gorus FK et al (1998) Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 41:452–459CrossRefPubMed

11.

Beuneu C, Vosters O, Movahedi B et al (2004) Human pancreatic duct cells exert tissue factor-dependent procoagulant activity: relevance to islet transplantation. Diabetes 53:1407–1411CrossRefPubMed

12.

Vosters O, Beuneu C, Nagy N et al (2004) CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia 47:660–668CrossRefPubMed

13.

Pavlovic D, van de Winkel M, van der Auwera B et al (1997) Effect of interferon-gamma and glucose on major histocompatibility complex class I and class II expression by pancreatic beta- and non-beta-cells. J Clin Endocrinol Metab 82:2329–2336CrossRefPubMed

14.

Pavlovic D, Chen MC, Bouwens L, Eizirik DL, Pipeleers D (1999) Contribution of ductal cells to cytokine responses by human pancreatic islets. Diabetes 48:29–33CrossRefPubMed

15.

Movahedi B, Van de Casteele M, Caluwé N et al (2004) Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia 47:998–1008CrossRefPubMed

16.

Lau J, Mattsson G, Carlsson C et al (2007) Implantation site-dependent dysfunction of transplanted pancreatic islets. Diabetes 56:1544–1550CrossRefPubMed

17.

Lee Y, Ravazzola M, Park BH, Bashmakov YK, Orci L, Unger RH (2007) Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. Diabetes 56:2295–2301CrossRefPubMed

18.

Desai N, Goss J, Deng S et al (2003) Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 76:1623–1625CrossRefPubMed

19.

Ao Z, Matayoshi K, Lakey JR, Rajotte RV, Warnock GL (1993) Survival and function of purified islets in the omental pouch site of outbred dogs. Transplantation 56:524–529CrossRefPubMed

20.

Berman DM, O’Neil JJ, Coffey LC et al (2009) Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant 9:91–104CrossRefPubMed

21.

Gustavson S, Rajotte RV, Hunkeler D et al (2005) Islet auto-transplantation into an omental or splenic site results in a normal beta cell but abnormal alpha cell response to mild non-insulin-induced hypoglycemia. Am J Transplant 5:2368–2377CrossRefPubMed

22.

Hefty TR, Kuhr CS, Chong KT et al (2008) Omental roll-up: a technique for islet engraftment in a large animal model. J Surg Res. doi:10.1016/j.jss.2008.11.842 PubMed

23.

Kin T, Korbutt GS, Rajotte RV (2003) Survival and metabolic function of syngeneic rat islet grafts transplanted in the omental pouch. Am J Transplant 3:281–285CrossRefPubMed

24.

Yasunami Y, Lacy PE, Finke EH (1983) A new site for islet transplantation—a peritoneal–omental pouch. Transplantation 36:181–182CrossRefPubMed

25.

Pipeleers DG, Pipeleers-Marichal M, Hannaert JC et al (1991) Transplantation of purified islet cells in diabetic rats. I. Standardization of islet cell grafts. Diabetes 40:908–919CrossRefPubMed

26.

Ling Z, Pipeleers DG (1996) Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest 98:2805–2812CrossRefPubMed

27.

Merino JF, Nacher V, Raurell M, Biarnés M, Soler J, Montanya E (2000) Optimal insulin treatment in syngeneic islet transplantation. Cell Transplant 9:11–18PubMed

28.

Clark PM (1999) Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 36:541–564PubMed

29.

Mattsson G, Carlsson PO, Olausson K, Jansson L (2002) Histological markers for endothelial cells in endogenous and transplanted rodent pancreatic islets. Pancreatology 2:155–162CrossRefPubMed

30.

Carlow DA, Gold MR, Ziltener HJ (2009) Lymphocytes in the peritoneum home to the omentum and are activated by resident dendritic cells. J Immunol 183:1155–1165CrossRefPubMed

31.

Korsgren O, Jansson L (1994) Porcine islet-like cell clusters cure diabetic nude rats when transplanted under the kidney capsule, but not when implanted into the liver or spleen. Cell Transplant 3:49–54PubMed

32.

Lin Y, Goebels J, Xia G, Ji P, Vandeputte M, Waer M (1998) Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nat Med 4:173–180CrossRefPubMed

33.

Moberg L, Johansson H, Lukinius A et al (2002) Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360:2039–2045CrossRefPubMed

34.

Jansson L, Carlsson P-O (2002) Graft vascular function after transplantation of pancreatic islets. Diabetologia 45:749–763CrossRefPubMed

35.

Mattsson G, Jansson L, Carlsson P-O (2002) Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 51:1362–1366CrossRefPubMed

36.

Merani S, Toso C, Emamaullee J, Shapiro A (2008) Optimal implantation site for pancreatic islet transplantation. B J Surg 95:1449–1461CrossRef

Title: Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity
Authors: D. Jacobs-Tulleneers-Thevissen
K. Bartholomeus
K. Suenens
I. Vermeulen
Z. Ling
K. H. Hellemans
P. In’t Veld
M. Pipeleers-Marichal
D. Pipeleers
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1721-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties